Trial record 8 of 126 for:    Orthostatic Hypotension

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chelsea Therapeutics
ClinicalTrials.gov Identifier:
NCT01176240
First received: July 30, 2010
Last updated: April 22, 2014
Last verified: April 2014

July 30, 2010
April 22, 2014
June 2010
October 2012   (final data collection date for primary outcome measure)
  • 306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]

    The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.

    For the change from baseline, negative numbers represent improvement from baseline in OHQ score.

  • 306B Efficacy: Change in Dizziness/Lightheadedness/Feeling Faint/Feeling Like You Might Black Out (OHSA Item 1) [ Time Frame: Baseline, Week1 ] [ Designated as safety issue: No ]
    OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.
Efficacy [ Time Frame: Baseline to End of Study (approximately 8 Weeks) ] [ Designated as safety issue: No ]
The primary efficacy variable is the relative mean change in the Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study (Approximately 8 weeks of treatment)
Complete list of historical versions of study NCT01176240 on ClinicalTrials.gov Archive Site
  • 306B Efficacy: Change in OHSA Item 1 From Baseline to Week 2 (Visit 5) [ Time Frame: Baseline, Week2 ] [ Designated as safety issue: No ]
    OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.
  • 306B Efficacy: Change in OHSA Item 1 From Baseline to Week 4 (Visit 6) [ Time Frame: Baseline, Week4 ] [ Designated as safety issue: No ]
    OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.
  • 306B Efficacy: Change in Systolic Blood Pressure (SBP) Measurements Post Standing From Baseline to Week 1 [ Time Frame: Baseline, Week 1 ] [ Designated as safety issue: No ]
    Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline.
  • 306B Efficacy: Change in OHSA Item 1 From Baseline to Week 8 (Visit 7) [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]
    OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline.
  • 306B Efficacy: Rate of Patient Reported Falls [ Time Frame: up to 10 weeks ] [ Designated as safety issue: Yes ]
    The average number of patient reported falls per week.
  • 306B Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ) [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]

    The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.

    For the change from baseline, negative numbers represent improvement from baseline in OHQ score.

Efficacy [ Time Frame: Baseline to End of Study (Approximately 8 weeks of treatment) ] [ Designated as safety issue: Yes ]
Baseline to end of study (Approximately 8 weeks): Relative mean change in OHSA composite and OHSA items 1 to 6 (symptom) and OHDAS composite and OHDAS items 1 to 4 (activity) scores; Relative mean change in Global assessment evaluations using the clinician-recorded and patient-recorded CGI-S scales; Change in standing blood pressure; Change in standing time. Global assessment of improvement of disease status using the clinician and patient-recorded CGI-I scales at end of study; Number of patients reporting falls as well as the total number of reported falls during the 8 week treatment period.
Not Provided
Not Provided
 
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug.

Symptoms of NOH may include any of the following:

  • Dizziness, light-headedness, feeling faint or feeling like you may blackout
  • Problems with vision (blurring, seeing spots, tunnel vision, etc.)
  • Weakness
  • Fatigue
  • Trouble concentrating
  • Head & neck discomfort (the coat hanger syndrome)
  • Difficulty standing for a short time or a long time
  • Trouble walking for a short time or a long time

The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.

Systolic blood pressure is transiently and minimally decreased in healthy individuals upon standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness and blurred or impaired vision, among other symptoms.

Orthostatic hypotension may be a severely disabling condition which can seriously interfere with the quality of life of afflicted subjects. Currently available therapeutic options provide some symptomatic relief in a subset of subjects, but are relatively ineffective and are often accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone, methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the pharmacological interventions that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of these currently available therapeutic options, and the incapacitating nature and often progressive downhill course of disease, point to the need for an improved therapeutic alternative.

Symptomatic OH in patients with Parkinson's disease is thought to be a consequence of norepinephrine depletion leading to low systolic blood pressure (SBP) and cerebral-hypoperfusion (reduced blood flow to the brain). Therapy with droxidopa results in increased levels of norepinephrine which should lead to improved SBP and cerebral perfusion thereby reducing the signs and symptoms of NOH. The present study will evaluate the clinical benefit in NOH patients with PD treated with droxidopa compared to those treated with placebo.

Participation in the study will last a maximum of 14 weeks consisting of a 2 week (maximum) screening/baseline period; a 2 week (maximum) double-blind dose titration; an 8 week double-blind placebo-controlled treatment period; and a 2 week follow-up period. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.

Droxidopa:

Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active. Stereoisomers and enantiomers are compounds that have the same chemical elements; however, they may react differently as the elements are positioned in different locations.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Orthostatic Hypotension
  • Parkinson's Disease
  • Drug: Droxidopa
    100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
    Other Names:
    • Northera
    • Droxidopa
    • L-DOPS
    • L-threo-dihydroxyphenylserine
    • SM-5688
  • Other: Placebo
    Placebo
    Other Name: Mannitol, Sugar Pill
  • Experimental: Droxidopa
    droxidopa active drug
    Intervention: Drug: Droxidopa
  • Placebo Comparator: Placebo
    Placebo matched control
    Intervention: Other: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
225
November 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. 18 years or over
  2. Clinical diagnosis of Parkinson's disease
  3. Clinical diagnosis of symptomatic neurogenic orthostatic hypotension

At their baseline visit (Visit 2), patients must demonstrate:

  • a score of at least 3 or greater on the OHQ composite
  • a score of at least 3 or greater on the clinician CGI-S
  • a fall of at least 20 mmHg in their systolic blood pressure, or 10 mmHg in their diastolic blood pressure, within 3 minutes of standing 4. Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care

Exclusion Criteria:

  1. Score of 23 or lower on the mini-mental state examination (MMSE)
  2. Concomitant use of vasoconstricting agents for the purpose of increasing blood pressure;

    - Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is longer) prior to their baseline visit (Visit 2) and throughout the duration of the study

  3. Concomitant use of anti-hypertensive medication for the treatment of essential hypertension
  4. Have changed dose, frequency or type of prescribed medication, within two weeks of baseline visit (Visit 2) with the following exceptions:

    • Vasoconstricting agents such a ephedrine, dihydroergotamine, or midodrine
    • Short courses (less than 2 weeks) of medications or treatments that do not interfere with, or exacerbate the patient's condition under study (e.g. antibiotics)
  5. Known or suspected alcohol or substance abuse within the past 12 months (DSM-IV definition of alcohol or substance abuse)
  6. Women who are pregnant or breastfeeding
  7. Women of child bearing potential (WOCP) who are not using at least one method of contraception with their partner
  8. Male patients who are sexually active with a woman of child bearing potential (WOCP) and not using at least one method of contraception
  9. Untreated closed angle glaucoma, or treated closed angle glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk to the patient
  10. Sustained severe hypertension (BP ≥ 180 mmHg systolic or ≥ 110 mmHg diastolic in the seated or supine position which is observed in 3 consecutive measurements over an hour)
  11. Any significant uncontrolled cardiac arrhythmia
  12. History of myocardial infarction, within the past 2 years
  13. Current unstable angina
  14. Congestive heart failure (NYHA Class 3 or 4)
  15. Diabetic autonomic neuropathy
  16. History of cancer within the past 2 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ
  17. Gastrointestinal condition, which in the Investigator's judgment, may affect the absorption of study drug (e.g. ulcerative colitis, gastric bypass)
  18. Any major surgical procedure within 30 days of the baseline visit (Visit 2)
  19. Previously treated with droxidopa
  20. Currently receiving any investigational drug or have received an investigational drug within 30 days of the baseline visit (Visit 2)
  21. Any condition or laboratory test result, which in the Investigator's judgment, might result in an increased risk to the patient, or would affect their participation in the study. Additionally the Investigator has the ability to exclude a patient if for any reason they feel the subject is not a good candidate for the study or will not be able to follow study procedures.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01176240
Droxidopa NOH306 (306A / 306B)
Yes
Chelsea Therapeutics
Chelsea Therapeutics
Not Provided
Principal Investigator: Robert Hauser, M.D. University of South Florida
Study Chair: Lawrence A. Hewitt, Ph.D. Chelsea Therapeutics, Inc.
Study Director: William Schwieterman, M.D. Chelsea Therapeutics, Inc.
Chelsea Therapeutics
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP